KEYNOTE-355 Final Analysis Reveals Survival Benefit With Pembrolizumab in Triple-Negative Breast Cancer
Last Updated: Tuesday, April 5, 2022
The final overall survival results from the KEYNOTE-355 study showed a statistically significant 27% reduction in the risk of death for patients with metastatic triple-negative breast cancer whose tumors were strongly positive for PD-L1, defined as a combined positive score (CPS) of at least 10 and who received pembrolizumab vs placebo combined with chemotherapy as first-line therapy.
Advertisement
News & Literature Highlights